Abstract
The prevalence and clinical relevance of high on-treatment platelet reactivity especially in patients with acute myocardial infarction (AMI) and concomitant proton pump inhibitor (PPI) treatment have been controversially discussed in the literature [1], particularly since the U.S. Food and Drug Administration warning of potential negative interactions between clopidogrel and PPI metabolism (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety Informationfor PatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm079520.htm).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
